Trials in Progress

(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS

(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK

(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA

(P 532) MISTOSUS: A PHASE 2 STUDY OF ISCADOR® P IMMUNOTHERAPY FOR PATIENTS WITH RELAPSED OSTEOSARCOMA AND RESECTED PULMONARY METASTASES

(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.

(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA

(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH

(P 536) PHASE 1 STUDY OF DISULFIRAM WITH COPPER GLUCONATE AND LIPOSOMAL DOXORUBICIN IN PATIENTS WITH TREATMENT REFRACTORY SARCOMAS

(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA

(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL

(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)

(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS

(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")

(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR

(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING

(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)

(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)

(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)

(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)

(P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN

(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS

(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.

(P 553) A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS

(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS

(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS

(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA

(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS

(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)

(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN

(P 560) REAL-WORLD MONITORING OF PHYSICAL ACTIVITY USING AN ACCELEROMETER AFTER LOWER LIMB SURGERY FOR A SARCOMA.

(P 561) EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.

(P 562) A PHASE 2, SINGLE ARM STUDY OF REGORAFENIB IN METASTATIC/UNRESECTABLE REFRACTORY SYNOVIAL SARCOMAS

(P 563) BALANCE, GAIT AND BIOMECHANICAL COMPENSATIONS DURING DIFFERENT SPEEDS OF WALKING AFTER TREATMENT FOR DISTAL FEMORAL MUSCULOSKELETAL TUMOURS AND ASSOCIATED LIMITATIONS ON RETURN TO NORMAL LIVING

(P 564) A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS